Skin Cancers

FDA Grants Fast Track Designation to CMP-001 Combination in Advanced Melanoma

July 27, 2020

The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab plus ipilimumab under 2 melanoma indications.

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

July 26, 2020

A guideline from the American Society of Clinical Oncology addresses 4 clinical questions regarding approaches to systemic treatment for different types and stages of melanoma, in addition to summarizing the trials on which the recommendations were based.

Pembrolizumab Shows Long-Term Benefit in Advanced Melanoma Subgroups

July 17, 2020

A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.

Cemiplimab Upholds Efficacy in 3-Year Follow-up for Advanced Cutaneous Squamous Cell Carcinoma

July 01, 2020

In an interview with Targeted Oncology, Danny Rischin, MD, director, discussed the findings from the EMPOWER-CSCC-1 study of cemiplimab in advanced cutaneous squamous cell carcinoma that led to the drug’s FDA approval.

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

June 27, 2020

In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.

FDA Approves Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

June 24, 2020

Pembrolizumab received FDA approval for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by either surgery or radiation.

Fast Track Designation Granted to Seviprotimut-L Vaccine for Adjuvant Use in Stage IIB/IIC Melanoma

June 23, 2020

With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC

May 31, 2020

“The data demonstrated deepening clinical responses with cemiplimab over time. Furthermore, duration of response and overall survival [OS] are considerably longer with cemiplimab than what has previously been recorded with other agents.”

Early Trials in Melanoma Show Better Response After 1 Year

May 12, 2020

Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.

Cemiplimab Induces Significant Responses in Second-line Basal Cell Carcinoma

May 05, 2020

"...These important new results further demonstrate Libtayo’s potential in patients with difficult-to-treat, non-melanoma skin cancers."